ClinicalTrials.gg
RecruitingNCT07303686Updated Dec 26, 2025

De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis

A Phase 4 interventional study of Ustekinumab 90 mg SC q8w and Ustekinumab 90 mg SC q12w in Crohn Disease (CD) and Ulcerative Colitis (UC), sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
115
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing ustekinumab in Crohn Disease — 3 open to participants now, 5 under way, 2 of them phase 3. Ustekinumab · Crohn Disease.

Planned enrollment
12th of 21
115 · median 131
Started
2025
with 1 other
Phase 4
5 of 21
2 open now
Registered
21st of 21
by date
Lead sponsor
1 of 21
McGill University Health Centre/Research Institute of the McGill University Health Centre

Among the 21 studies testing ustekinumab in Crohn Disease, this one is the 12th largest by planned enrollment, is one of 2 that started in 2025, is one of 5 in phase 4, and was the 21st registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

3 of the 21 studies testing ustekinumab in Crohn Disease are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ustekinumab

Ustekinumab: first FDA approval 2009 (STELARA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing ustekinumab in Crohn Disease, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether disease remission can be maintained when biologic therapy is reduced in patients with Crohn"s disease (CD) and ulcerative colitis (UC) taking ustekinumab (UST).

The main question it aims to answer is:

Can we de-escalate UST subcutaneous dose either from every 4 weeks (Q4) to every 8 weeks (Q8) or every 8 weeks (Q8) to every 12 weeks (Q12) in CD or UC patients in deep remission without loosing their response? Researchers will follow UST blood levels, inflammation markers and intestinal mucosa integrity and to see if UST dose can be reduced while maintaining clinical remission.

Participants will:

Change UST dosing from Q4 to Q8 or from Q8 to Q12. Visit the clinic once every 12 weeks for checkups and tests.

Read the detailed description

Participation in this research study will last 12 months and will include 4-6 visits.

03

Conditions studied

  • Crohn Disease (CD)
  • Ulcerative Colitis (UC)

Keywords

  • CD
  • UC
  • ustekinumab
  • UST
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical remission
  • Biochemical remission
  • Endoscopy remission
  • Not on
  • A woman must be ;
  • not of
  • of childbearing potential and practicing a medically accepted method of .
  • Able t provide

Exclusion criteria

Exclusion Criteria:

  • On more than one biologics drug
  • Use of oral or topical within 6months of study entry
  • pregnancy
  • Any issue that could lead to non-compliance, as alcohol, drug use
  • Unable to provide consent or t comply with follw-up visit
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
115 participants (estimated)

Study arms

  • Other
    Ustekinumab Q4w

    Biological: Ustekinumab 90 mg SC q8w

  • Other
    Ustekinumab Q8w

    Biological: Ustekinumab 90 mg SC q12w

Interventions

06

What researchers measure

Primary outcomes

  1. Loss of clinical remission

    Proportion of patients experiencing loss of remission

    Time frame: From treatment switch to end of participation (12 months)

Secondary outcomes

  1. Time-to-loss of Remission

    Time frame: From treatment switch to end of participation (12 months)

  2. Change from Baseline in the C-reactive protein (CRP) level at loss of remission.

    To define if CRP level is a predictor of loss of remission.

    Time frame: 12 months

  3. Change from Baseline in the calprotectin level at loss of remission.

    To define if calprotectin level is a predictor of loss of remission.

    Time frame: 12 months

  4. Disease duration before loss of remission.

    Define if disease duration is a predictor of loss of remission.

    Time frame: Up to 50 years.

  5. Change in drug concentration before loss of remission.

    Define if drug concentration in blood is a predictor of loss of remission.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Apr 2027, 18 months after the start.

Of 54 non-industry phase 4 interventional studies under Crohn Disease, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 71. This study's planned 18 months is below that.

Counting every sponsor, half of 70 studies reached it within 56 months; a quarter within 35 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2025
First posted
Dec 26, 2025
StartActual
Oct 8, 2025
Primary completionEst.
Apr 15, 2027
CompletionEst.
Oct 15, 2027
Last update
Dec 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07303686
Collaborators
Janssen Inc.
Responsible party
waqqas.afif (Principal Investigator, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Dec 26, 2025
Start date
Oct 8, 2025
Primary completion
Apr 15, 2027 (estimated)
Completion
Oct 15, 2027 (estimated)
Last update
Dec 26, 2025

Study contacts

Waqqas Afif, MD
Contact
waqqas.afif@mcgill.ca
514-934-1943 ext. 36536

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ustekinumab

Start the discussion